The inherent positivity of CD56 in NKTCL has also been observed; although no therapeutic target to CD56 currently exists, a study in solid tumors identified that higher expression of CD56 were observed in responders to anti-PD-1/PD-L1 therapy (160). The gene discussed is PDCD1; the disease is extranodal nasal NK/T cell lymphoma.